Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD8965 Phase 2b study in idiopathic pulmonary fibrosis
MOH_2026-05-17_015825Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AZD8965 in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by AstraZeneca. Started May 2026; status: recruiting.
02
Drugs
AZD8965
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on MOH_2026-05-17_015825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-05-17_015825.